Abstract
Twenty-eight patients with healed duodenal ulcer completed a 12-month double-blind trial to compare the effects of pirenzepine (25 mg twice daily) and placebo on the prevention of duodenal ulcer relapse. Seven of those on pirenzepine had endoscopically proven recurrent ulcer within a mean of 5 months, while 9 of those on placebo had one after a mean of 5.7 months (n.s.). No untoward effects which could be attributed to the drug were observed during the whole period of treatment.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Adult
-
Aged
-
Anti-Ulcer Agents / therapeutic use*
-
Benzodiazepinones / therapeutic use*
-
Clinical Trials as Topic
-
Double-Blind Method
-
Duodenal Ulcer / drug therapy
-
Duodenal Ulcer / epidemiology
-
Duodenal Ulcer / prevention & control*
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Piperazines / therapeutic use*
-
Pirenzepine
-
Placebos
-
Recurrence
-
Time Factors
Substances
-
Anti-Ulcer Agents
-
Benzodiazepinones
-
Piperazines
-
Placebos
-
Pirenzepine